117 related articles for article (PubMed ID: 10526874)
1. Creatinine at the evaluation of urinary 1-methyladenosine and pseudouridine excretion.
Honda I; Itoh K; Mizugaki M; Sasaki T
Tohoku J Exp Med; 1999 Jun; 188(2):133-8. PubMed ID: 10526874
[TBL] [Abstract][Full Text] [Related]
2. Relationship of urinary pseudouridine and 1-methyladenosine to activity of leukemia and lymphoma.
Itoh K; Konno T; Sasaki T; Ishiwata S; Ishida N; Misugaki M
Clin Chim Acta; 1992 Mar; 206(3):181-9. PubMed ID: 1606704
[TBL] [Abstract][Full Text] [Related]
3. Urinary excretion patterns of modified nucleosides, pseudouridine and 1-methyladenosine, in healthy individuals.
Itoh K; Aida S; Ishiwata S; Sasaki S; Ishida N; Mizugaki M
Clin Chim Acta; 1993 Aug; 217(2):221-3. PubMed ID: 8261632
[No Abstract] [Full Text] [Related]
4. An immunohistochemical analysis for cancer of the esophagus using monoclonal antibodies specific for modified nucleosides.
Masuda M; Nishihira T; Itoh K; Mizugaki M; Ishida N; Mori S
Cancer; 1993 Dec; 72(12):3571-8. PubMed ID: 8252470
[TBL] [Abstract][Full Text] [Related]
5. Comparison of urinary neopterin and pseudouridine in patients with malignant proliferative diseases.
Motyl T; Traczyk Z; Holska W; Daniewska-Michalska D; Cieśluk S; Kukulska W; Kałuzny Z; Podgurniak M
Eur J Clin Chem Clin Biochem; 1993 Apr; 31(4):205-9. PubMed ID: 8318566
[TBL] [Abstract][Full Text] [Related]
6. Preparation of a monoclonal antibody specific for 1-methyladenosine and its application for the detection of elevated levels of 1-methyladenosine in urines from cancer patients.
Itoh K; Mizugaki M; Ishida N
Jpn J Cancer Res; 1988 Oct; 79(10):1130-8. PubMed ID: 3143701
[TBL] [Abstract][Full Text] [Related]
7. Quantitation of urinary nucleosides by high-performance liquid chromatography.
Liebich HM; Di Stefano C; Wixforth A; Schmid HR
J Chromatogr A; 1997 Feb; 763(1-2):193-7. PubMed ID: 9129323
[TBL] [Abstract][Full Text] [Related]
8. Urinary modified nucleosides as tumor markers in cancer of the urinary organs or female genital tract.
Koshida K; Harmenberg J; Stendahl U; Wahren B; Borgström E; Helström L; Andersson L
Urol Res; 1985; 13(5):213-8. PubMed ID: 4060364
[TBL] [Abstract][Full Text] [Related]
9. Detection of elevated amounts of urinary pseudouridine in cancer patients by use of a monoclonal antibody.
Itoh K; Mizugaki M; Ishida N
Clin Chim Acta; 1989 May; 181(3):305-15. PubMed ID: 2758683
[TBL] [Abstract][Full Text] [Related]
10. Relationship between urinary excretion of modified nucleosides and rheumatoid arthritis process.
Tebib JG; Reynaud C; Cedoz JP; Letroublon MC; Niveleau A
Br J Rheumatol; 1997 Sep; 36(9):990-5. PubMed ID: 9376997
[TBL] [Abstract][Full Text] [Related]
11. [Serum 1-methyladenosine and pseudouridine as tumor markers in tumor-bearing mice].
Ishiwata S; Itoh K; Yamaguchi T; Sasaki S; Ishida N; Mizugaki M
Yakugaku Zasshi; 1995 Jul; 115(7):523-7. PubMed ID: 7562399
[TBL] [Abstract][Full Text] [Related]
12. [Molecular and immunological approach to hematological disease: detection and analysis of intracellular modified nucleosides by flow cytometry].
Hoshino A; Honda I; Ishimori A; Itoh K; Mizugaki M; Nose M
Rinsho Byori; 1990 Jul; 38(7):756-64. PubMed ID: 2402080
[TBL] [Abstract][Full Text] [Related]
13. Comparison of serum and urinary levels of modified nucleoside, 1-methyladenosine, in cancer patients using a monoclonal antibody-based inhibition ELISA.
Ishiwata S; Itoh K; Yamaguchi T; Ishida N; Mizugaki M
Tohoku J Exp Med; 1995 May; 176(1):61-8. PubMed ID: 7482520
[TBL] [Abstract][Full Text] [Related]
14. Correlations of pseudouridine in 8-hour and 24-hour urinary samples determined by high-performance liquid chromatography.
Sjølin KE
Urol Res; 1982; 10(5):245-8. PubMed ID: 7164220
[TBL] [Abstract][Full Text] [Related]
15. [The clinical significance of pseudouridine determination of the urine in children and adolescents].
Graf N; Bach K; Frisch B; Haas HJ; Sitzmann FC
Klin Padiatr; 1989; 201(3):154-62. PubMed ID: 2739340
[TBL] [Abstract][Full Text] [Related]
16. Blood plasma pseudouridine in patients with malignant proliferative diseases.
Motyl T; Traczyk Z; Cieśluk S; Daniewska-Michalska D; Kukulska W; Kałuzny Z; Podgurniak M; Orzechowski A; Debski B
Eur J Clin Chem Clin Biochem; 1993 Nov; 31(11):765-71. PubMed ID: 8305621
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic use of anti-modified nucleoside monoclonal antibody.
Itoh K; Ishiwata S; Ishida N; Mizugaki M
Tohoku J Exp Med; 1992 Oct; 168(2):329-31. PubMed ID: 1306318
[TBL] [Abstract][Full Text] [Related]
18. Urinary pseudouridine/creatinine ratio as an indicator of gastrointestinal cancer.
Higley B; De Mello J; Oakes DJ; Giles GR
Br J Surg; 1982 Dec; 69(12):699-701. PubMed ID: 7171969
[TBL] [Abstract][Full Text] [Related]
19. Relationship of urinary excretion of modified nucleosides to disease status in childhood acute lymphoblastic leukemia.
Heldman DA; Grever MR; Miser JS; Trewyn RW
J Natl Cancer Inst; 1983 Aug; 71(2):269-73. PubMed ID: 6576186
[TBL] [Abstract][Full Text] [Related]
20. Patterns of urinary excretion of modified nucleosides.
Gehrke CW; Kuo KC; Waalkes TP; Borek E
Cancer Res; 1979 Apr; 39(4):1150-3. PubMed ID: 421198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
